ZimVie Inc. ZIMV

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
59/100
Moderate

Ranked against 159 peers in Medical Devices

Key strengths

  • Strong FCF Generation FCF margin quality is top-tier vs peers (score 0.71). High FCF conversion confirms strong earnings quality.
  • Strong Operating Margin vs Peers Operating margin level is strong vs peers (score 0.72). SG&A discipline is converting gross margin into operating profit efficiently.

Key risks

  • Declining FCF Margin FCF trend score is negative (score 0.35). Declining FCF margin warrants scrutiny of capital allocation discipline.
  • Declining Capital Returns ROIC durability is weak (score 0.00). Volatility or decline in returns is a leading moat erosion signal.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
63
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where ZIMV ranks in Medical Devices

ZimVie Inc. ranks #49 of 160 scored companies in Medical Devices by moat score — the top 31%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

# Company Moat score Rating
45 Neuropace, Inc. NPCE 61/100 Moderate
46 VolitionRX Limited VNRX 60/100 Moderate
47 NovoCure Limited NVCR 60/100 Moderate
48 Establishment Labs Holdings Inc ESTA 60/100 Moderate
49 ZimVie Inc. ZIMV 59/100 Moderate
50 AdaptHealth Corp. AHCO 59/100 Moderate
51 Sight Sciences, Inc. SGHT 59/100 Moderate
52 Treace Medical Concepts, Inc. TMCI 58/100 Moderate
53 WORK Medical Technology Group L WOK 58/100 Moderate

See every Medical Devices & Diagnostics company ranked by moat score →

How ZIMV scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 63 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 64 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 55 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 58 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 54 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 61 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding ZIMV's moat

What is ZimVie Inc.'s moat score?

ZimVie Inc. (ZIMV) scores 59 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #49 of 160 scored companies in Medical Devices, the top 31%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is R&D Pipeline & Capital Returns (64/100) and its weakest is Capital Structure & Resilience (54/100).

How does ZimVie Inc. compare with other Medical Devices companies?

ZimVie Inc. ranks #49 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Establishment Labs Holdings Inc (ESTA) at 60 just above it and AdaptHealth Corp. (AHCO) at 59 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is ZimVie Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for ZimVie Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and ZIMV scores: Pricing Power & Consumable Moat (63), R&D Pipeline & Capital Returns (64), FCF Quality & Cash Conversion (55), Commercial Execution (58), Capital Structure & Resilience (54), Growth Durability (61). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000